Litcius/Paper detail

Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model

Jana Jandová, Georg T. Wondrak

2021Journal of Investigative Dermatology18 citationsDOIOpen Access PDF

Topics & Concepts

Cancer researchVemurafenibNeuroblastoma RAS viral oncogene homologDownregulation and upregulationMelanomaEpithelial–mesenchymal transitionCarcinogenesisMetastasisBiologyCancerMedicineInternal medicineKRASGeneBiochemistryColorectal cancerMetastatic melanomaMelanoma and MAPK PathwaysComputational Drug Discovery MethodsCytokine Signaling Pathways and Interactions
Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model | Litcius